Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
NCT00269412
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
525
Enrollment
INDUSTRY
Sponsor class
Conditions
Irritable Bowel Syndrome
Interventions
DRUG:
Rifaximin
Sponsor
Bausch Health Americas, Inc.